Clinical Benefit of Self-Monitoring of Blood Glucose Is Uncertain for Non–Insulin-Treated Patients With Type 2 Diabetes

Abstract

C: Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin 25:2903-2913, 2009 SUMMARY Design. A comprehensive systematic review and meta-analysis. Objective. To assess the effect of self-monitoring of blood glucose (SMBG) on A1C in non-insulintreated patients with type 2 diabetes. Subjects. The analysis included 3,270 non-insulin-treated patients with type 2 diabetes in Canada, the United States, Europe, and Asia. In the 15 studies included, mean age ranged from 50 to 67 years, with 38-74% female patients. Mean duration of diabetes ranged from 0 to 12.5 years. Mean BMI ranged from 27.1 to 34.2 kg/m 2 , and baseline A1C ranged from 6.7 to 11.9%. Methods. Studies included randomized, controlled trials of non-insulin-treated type 2 diabetic patients comparing treatment strategies including SMBG to less frequent or no SMBG. To be included, trials also had to report data on A1C. Two independent reviewers assessed study quality, with any discrepancies resolved by a third reviewer. The authors used heterogeneity statistics (I 2) to determine the appropriate model for analysis, with high

The Efficacy of Tele-Monitoring in Maintaining Glycated Haemoglobin Levels in Patients with Type 2 Diabetes Mellitus: A Systematic Review

“…Interestingly, the systematic review by Gerrald et al [ 51 ], found no benefit of telemonitoring in improving HbA1c and reported that HbA1c was unaffected by education aimed at self-management and study follow-up. This was also the case in some of the selected papers for this systematic review that reported no statistically significant benefit of education in improving HbA1c.…”

Self-monitoring of blood glucose in Black Caribbean and South Asian Canadians with non-insulin treated Type 2 diabetes mellitus: a qualitative study of patients’ perspectives

“…Most of the participants in our study were under the age of 65 and therefore not covered by the Ontario Drug Plan, which reimburses SMBG expenses. There is mounting evidence that SMBG is not cost-effective and many advocate that the frequency of SMBG for patients with Type 2 DM not treated with insulin should be limited (i.e., 1–2 times per week) [ 12 , 37 ], which can incur a substantial reduction in expenditures [ 17 ]. In response to this evidence, the Canadian Diabetes Association released more specific SMBG guidelines stating that patients who are not treated with insulin, have stable and controlled blood glucose levels, and are not at risk of hypoglycemia would benefit from performing SMBG less than 2 times per week [ 38 ].…”

Perspektien digitaler Diabetesprävention: wo wollen wir hin?

“…Unter ärztlicher Supervision sind Patienten dabei angehalten, ihre eigenen Blutzuckerwerte regel mäßig zu erheben und zu protokollieren. Die so erhobenen Daten erlauben es, einen stetigen Krankheitsverlauf sicher zustellen, da auf auffällige Werte zeitgerecht reagiert werden kann [16].…”